Skip to main content

Table 3 Univariate analysis of disease free survival among patients with baseline BMI ≥ 23 kg/m2 (N = 338)

From: Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients

  

Unadjusted HR (95 % CI)

p-value

Sex

Male

1.46 (0.82–2.63)

0.20

Female

1

 

Age

≥ 65 years

1.09 (0.62–1.90)

0.77

< 65 years

1

 

Body weight change

Gain ≥ 5 kg

2.01 (1.01–3.99)

0.047

Others

1

 

Location

Proximal

0.85 (0.48–1.50)

0.57

Distal

1

 

Stage

III

1.32 (0.53–3.31)

0.55

II

1

 

T stage

T 4

2.53 (1.36–4.72)

0.004

T 1–3

1

 

N stage

N 2

2.96 (1.74–5.05)

<0.001

N 0–1

1

 

Angiolymphatic invasion

Present

3.87 (2.11–7.12)

<0.001

Absent

1

 

Venous invasion

Present

2.50 (1.26–4.98)

0.009

Absent

1

 

Perineural invasion

Present

3.53 (2.05–6.07)

<0.001

Absent

1

 

Histology

MAC

1.35 (0.42–4.34)

0.61

Non-MAC

1

 

Microsatellite status

MSI-H

0.70 (0.17–2.87)

0.62

MSS/MSI-L

1

 
  1. Abbreviations: HR hazard ratio, CI confidence interval, MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
Back to article page